Kailera Therapeutics, Inc. (NASDAQ:KLRA)
| Market Cap | 1.50B-55.4% |
| Revenue (ttm) | 0 |
| Net Income | -190.17M |
| EPS | -1.76 |
| Shares Out | 129.57M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,181,033 |
| Open | 10.13 |
| Previous Close | 10.00 |
| Day's Range | 9.98 - 11.80 |
| 52-Week Range | 9.76 - 28.23 |
| Beta | 0.50 |
| Analysts | n/a |
| Price Target | 42.00(+261.76%) |
| Earnings Date | n/a |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About KLRA
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$KLRA stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in KLRA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by KLRA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
KLRA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New KLRA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to KLRA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in KLRA
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $18.18M |
| VBVanguard Morningstar Small-Cap ETF | $13.14M |
| XBIState Street SPDR S&P Biotech ETF | $12.68M |
| IWMiShares Russell 2000 ETF | $12.20M |
| VBKVanguard Morningstar Small-Cap Growth ETF | $7.50M |
| VXFVanguard Extended Market ETF | $7.42M |
Estimated from each fund’s disclosed top holdings × AUM
KLRA Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from KLRA’s recent data — informational, not investment advice